Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 SALES VALUE AND VOLUME
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTAL ANALYSIS
5.2 PORTER’S FIVE FORCES
5.3 KEY STRATEGIC INITIATIVES
6 INDUSTRY INSIGHTS
7 REGULATORY FRAMWORK
8 EPIDEMIOLOGY
9 PIPELINE ANALYSIS
9.1 PHASE I CANDIDATES
9.2 PHASE II CANDIDATES
9.3 PHASE III CANDIDATES
9.4 OTHERS ( PRE-CLINICAL AND RESEARCH)
10 GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, BY TREATMENT TYPE
10.1 OVERVIEW
(MARKET SIZE (USD MILLION), MARKET VOLUME (UNITS) AND AVERAGE SELLING PRICE (USD) WILL BE PROVIDED FOR BELOW ALL SEGMENTS)
10.2 ANTIMALARIAL DRUGS (HYDROXYCHLOROQUINE)
10.3 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
10.3.1 NAPROXEN SODIUM
10.3.2 IBUPROFEN
10.3.3 MOTRIN IB
10.3.4 OTHERS
10.4 CYTOTOXIC AND IMMUNOSUPPRESSIVE DRUGS
10.4.1 AZATHIOPRINE
10.4.2 MYCOPHENOLATE
10.4.3 METHOTREXATE
10.4.4 CYCLOSPORINE
10.4.5 LEFLUNOMIDE
10.5 DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
10.5.1 BARICITINIB
10.5.2 TOFACITINIB
10.5.3 ADALIMUMAB
10.5.4 METHOTREXATE
10.6 STERIODS
10.6.1 CORTICOSTEROIDS
10.6.2 GLUCOCORTICOIDS
10.6.3 METHYLPREDNISOLONE
10.7 ANTICOAGULANTS
10.7.1 ASPIRIN
10.7.2 WARFARIN
10.7.3 HEPARIN
10.8 MONOCLONAL ANTIBODIES ( BELIMUNMAB)
10.9 OTHERS
11 GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, BY DIAGNOSIS
11.1 OVERVIEW
11.2 LABORATORY TESTS
11.2.1 BLOOD TESTS
11.2.1.1. CBC
11.2.1.2. ERYTHROCYTE SEDIMENTATION RATE
11.2.1.3. OTHERS
11.2.2 ANTINUCLEAR ANTIBODY TEST
11.2.3 URINALYSIS
11.2.4 OTHERS
11.3 IMAGING TESTS
11.3.1 X-RAY
11.3.2 ECHOCARDIOGRAM
11.3.3 OTHERS
11.4 OTHERS
12 GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 BRANDED
12.2.1 ALEVE
12.2.2 ADVIL
12.2.3 PLAQUENIL
12.2.4 MEDROL
12.2.5 IMURAN
12.2.6 AZASEN
12.2.7 CELLCEPT
12.2.8 TREXALL
12.2.9 ARAVA
12.2.10 OTHERS
12.3 GENERICS
13 GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, BY DOSAGE FORM
13.1 OVERVIEW
13.2 TABLET
13.3 CAPSULES
13.4 INJECTIONS
13.5 OTHERS
14 GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, BY PRESCRIPTION TYPE
14.1 OVERVIEW
14.2 PRESCRIPTION
14.3 BRANDED
14.4 GENERIC
14.5 OVER THE COUNTER
15 GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 ORAL
15.2.1 TABLET
15.2.2 CAPSULES
15.2.3 OTHERS
15.3 INTRAVENOUS
15.3.1 INTRAVENOUS
15.3.2 SUBCUTANEOUS
15.3.3 OTHERS
15.4 TOPICAL
16 GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, BY POPULATION TYPE
16.1 OVERVIEW
16.2 CHILDREN
16.3 ADULTS
16.3.1 FEMALE
16.3.2 MALE
16.4 GERIATRIC
16.4.1 FEMALE
16.4.2 MALE
17 GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, BY END USER
17.1 OVERVIEW
17.2 HOSPITALS
17.3 CLINICS
17.4 DIAGNOSTIC CENTRES
17.5 HOME CARE SETTINGS
17.6 OTHERS
18 GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 HOSPITAL PHARMACY
18.3 RETAIL PHARMACY
18.4 ONLINE PHARMACY
18.5 OTHERS
19 GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, BY GEOGRAPHY
GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
19.1 NORTH AMERICA
19.1.1 U.S.
19.1.2 CANADA
19.1.3 MEXICO
19.2 EUROPE
19.2.1 GERMANY
19.2.2 U.K.
19.2.3 ITALY
19.2.4 FRANCE
19.2.5 SPAIN
19.2.6 RUSSIA
19.2.7 SWITZERLAND
19.2.8 TURKEY
19.2.9 BELGIUM
19.2.10 NETHERLANDS
19.2.11 DENMARK
19.2.12 SWEDEN
19.2.13 POLAND
19.2.14 NORWAY
19.2.15 FINLAND
19.2.16 REST OF EUROPE
19.3 ASIA-PACIFIC
19.3.1 JAPAN
19.3.2 CHINA
19.3.3 SOUTH KOREA
19.3.4 INDIA
19.3.5 SINGAPORE
19.3.6 THAILAND
19.3.7 INDONESIA
19.3.8 MALAYSIA
19.3.9 PHILIPPINES
19.3.10 AUSTRALIA
19.3.11 NEW ZEALAND
19.3.12 VIETNAM
19.3.13 TAIWAN
19.3.14 REST OF ASIA-PACIFIC
19.4 SOUTH AMERICA
19.4.1 BRAZIL
19.4.2 ARGENTINA
19.4.3 REST OF SOUTH AMERICA
19.5 MIDDLE EAST AND AFRICA
19.5.1 SOUTH AFRICA
19.5.2 EGYPT
19.5.3 BAHRAIN
19.5.4 UNITED ARAB EMIRATES
19.5.5 KUWAIT
19.5.6 OMAN
19.5.7 QATAR
19.5.8 SAUDI ARABIA
19.5.9 REST OF MEA
19.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
20 GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, SWOT AND DBMR ANALYSIS
21 GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, COMPANY LANDSCAPE
21.1 COMPANY SHARE ANALYSIS: GLOBAL
21.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
21.3 COMPANY SHARE ANALYSIS: EUROPE
21.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
21.5 MERGERS & ACQUISITIONS
21.6 NEW PRODUCT DEVELOPMENT & APPROVALS
21.7 EXPANSIONS
21.8 REGULATORY CHANGES
21.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
22 GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, COMPANY PROFILE
22.1 BRISTOL-MYERS SQUIBB COMPANY
22.1.1 COMPANY OVERVIEW
22.1.2 REVENUE ANALYSIS
22.1.3 GEOGRAPHIC PRESENCE
22.1.4 PRODUCT PORTFOLIO
22.1.5 RECENT DEVELOPMENTS
22.2 MERCK & CO., INC.,
22.2.1 COMPANY OVERVIEW
22.2.2 REVENUE ANALYSIS
22.2.3 GEOGRAPHIC PRESENCE
22.2.4 PRODUCT PORTFOLIO
22.2.5 RECENT DEVELOPMENTS
22.3 GLAXOSMITHKLINE PLC.
22.3.1 COMPANY OVERVIEW
22.3.2 REVENUE ANALYSIS
22.3.3 GEOGRAPHIC PRESENCE
22.3.4 PRODUCT PORTFOLIO
22.3.5 RECENT DEVELOPMENTS
22.4 F. HOFFMANN-LA ROCHE LTD.
22.4.1 COMPANY OVERVIEW
22.4.2 REVENUE ANALYSIS
22.4.3 GEOGRAPHIC PRESENCE
22.4.4 PRODUCT PORTFOLIO
22.4.5 RECENT DEVELOPMENTS
22.5 ANTHERA PHARMACEUTICALS, INC.
22.5.1 COMPANY OVERVIEW
22.5.2 REVENUE ANALYSIS
22.5.3 GEOGRAPHIC PRESENCE
22.5.4 PRODUCT PORTFOLIO
22.5.5 RECENT DEVELOPMENTS
22.6 ELI LILLY AND COMPANY
22.6.1 COMPANY OVERVIEW
22.6.2 REVENUE ANALYSIS
22.6.3 GEOGRAPHIC PRESENCE
22.6.4 PRODUCT PORTFOLIO
22.6.5 RECENT DEVELOPMENTS
22.7 PFIZER INC.
22.7.1 COMPANY OVERVIEW
22.7.2 REVENUE ANALYSIS
22.7.3 GEOGRAPHIC PRESENCE
22.7.4 PRODUCT PORTFOLIO
22.7.5 RECENT DEVELOPMENTS
22.8 LYCERA
22.8.1 COMPANY OVERVIEW
22.8.2 REVENUE ANALYSIS
22.8.3 GEOGRAPHIC PRESENCE
22.8.4 PRODUCT PORTFOLIO
22.8.5 RECENT DEVELOPMENTS
22.9 MYLAN N.V.
22.9.1 COMPANY OVERVIEW
22.9.2 REVENUE ANALYSIS
22.9.3 GEOGRAPHIC PRESENCE
22.9.4 PRODUCT PORTFOLIO
22.9.5 RECENT DEVELOPMENTS
22.1 SANOFI
22.10.1 COMPANY OVERVIEW
22.10.2 REVENUE ANALYSIS
22.10.3 GEOGRAPHIC PRESENCE
22.10.4 PRODUCT PORTFOLIO
22.10.5 RECENT DEVELOPMENTS
22.11 AURINIA PHARMACEUTICALS INC.
22.11.1 COMPANY OVERVIEW
22.11.2 REVENUE ANALYSIS
22.11.3 GEOGRAPHIC PRESENCE
22.11.4 PRODUCT PORTFOLIO
22.11.5 RECENT DEVELOPMENTS
22.12 SANDOZ INTERNATIONAL GMBH
22.12.1 COMPANY OVERVIEW
22.12.2 REVENUE ANALYSIS
22.12.3 GEOGRAPHIC PRESENCE
22.12.4 PRODUCT PORTFOLIO
22.12.5 RECENT DEVELOPMENTS
22.13 NOVARTIS AG
22.13.1 COMPANY OVERVIEW
22.13.2 REVENUE ANALYSIS
22.13.3 GEOGRAPHIC PRESENCE
22.13.4 PRODUCT PORTFOLIO
22.13.5 RECENT DEVELOPMENTS
22.14 BAYER AG
22.14.1 COMPANY OVERVIEW
22.14.2 REVENUE ANALYSIS
22.14.3 GEOGRAPHIC PRESENCE
22.14.4 PRODUCT PORTFOLIO
22.14.5 RECENT DEVELOPMENTS
22.15 ZYDUS CADILA
22.15.1 COMPANY OVERVIEW
22.15.2 REVENUE ANALYSIS
22.15.3 GEOGRAPHIC PRESENCE
22.15.4 PRODUCT PORTFOLIO
22.15.5 RECENT DEVELOPMENTS
22.16 CORBUS PHARMACEUTICALS HOLDINGS INC.
22.16.1 COMPANY OVERVIEW
22.16.2 REVENUE ANALYSIS
22.16.3 GEOGRAPHIC PRESENCE
22.16.4 PRODUCT PORTFOLIO
22.16.5 RECENT DEVELOPMENTS
22.17 TRINITY BIOTECH
22.17.1 COMPANY OVERVIEW
22.17.2 REVENUE ANALYSIS
22.17.3 GEOGRAPHIC PRESENCE
22.17.4 PRODUCT PORTFOLIO
22.17.5 RECENT DEVELOPMENTS
22.18 EUROIMMUN AG
22.18.1 COMPANY OVERVIEW
22.18.2 REVENUE ANALYSIS
22.18.3 GEOGRAPHIC PRESENCE
22.18.4 PRODUCT PORTFOLIO
22.18.5 RECENT DEVELOPMENTS
22.19 BIOMÉRIEUX SA
22.19.1 COMPANY OVERVIEW
22.19.2 REVENUE ANALYSIS
22.19.3 GEOGRAPHIC PRESENCE
22.19.4 PRODUCT PORTFOLIO
22.19.5 RECENT DEVELOPMENTS
22.2 QUEST
22.20.1 COMPANY OVERVIEW
22.20.2 REVENUE ANALYSIS
22.20.3 GEOGRAPHIC PRESENCE
22.20.4 PRODUCT PORTFOLIO
22.20.5 RECENT DEVELOPMENTS
22.21 BIO-RAD LABORATORIES INC
22.21.1 COMPANY OVERVIEW
22.21.2 REVENUE ANALYSIS
22.21.3 GEOGRAPHIC PRESENCE
22.21.4 PRODUCT PORTFOLIO
22.21.5 RECENT DEVELOPMENTS
22.22 IMMUPHARMA PLC
22.22.1 COMPANY OVERVIEW
22.22.2 REVENUE ANALYSIS
22.22.3 GEOGRAPHIC PRESENCE
22.22.4 PRODUCT PORTFOLIO
22.22.5 RECENT DEVELOPMENTS
22.23 CORBUS PHARMACEUTICALS HOLDINGS, INC.
22.23.1 COMPANY OVERVIEW
22.23.2 REVENUE ANALYSIS
22.23.3 GEOGRAPHIC PRESENCE
22.23.4 PRODUCT PORTFOLIO
22.23.5 RECENT DEVELOPMENTS
22.24 PROTAGEN
22.24.1 COMPANY OVERVIEW
22.24.2 REVENUE ANALYSIS
22.24.3 GEOGRAPHIC PRESENCE
22.24.4 PRODUCT PORTFOLIO
22.24.5 RECENT DEVELOPMENTS
22.25 PROTALEX, INC.
22.25.1 COMPANY OVERVIEW
22.25.2 REVENUE ANALYSIS
22.25.3 GEOGRAPHIC PRESENCE
22.25.4 PRODUCT PORTFOLIO
22.25.5 RECENT DEVELOPMENTS
22.26 UCB SA
22.26.1 COMPANY OVERVIEW
22.26.2 REVENUE ANALYSIS
22.26.3 GEOGRAPHIC PRESENCE
22.26.4 PRODUCT PORTFOLIO
22.26.5 RECENT DEVELOPMENTS
22.27 XTL BIOPHARMACEUTICALS LTD.
22.27.1 COMPANY OVERVIEW
22.27.2 REVENUE ANALYSIS
22.27.3 GEOGRAPHIC PRESENCE
22.27.4 PRODUCT PORTFOLIO
22.27.5 RECENT DEVELOPMENTS
22.28 ASTRAZENECA
22.28.1 COMPANY OVERVIEW
22.28.2 REVENUE ANALYSIS
22.28.3 GEOGRAPHIC PRESENCE
22.28.4 PRODUCT PORTFOLIO
22.28.5 RECENT DEVELOPMENTS
22.29 TEVA PHARMACEUTICAL
22.29.1 COMPANY OVERVIEW
22.29.2 REVENUE ANALYSIS
22.29.3 GEOGRAPHIC PRESENCE
22.29.4 PRODUCT PORTFOLIO
22.29.5 RECENT DEVELOPMENTS
22.3 ZYDUS CADILA
22.30.1 COMPANY OVERVIEW
22.30.2 REVENUE ANALYSIS
22.30.3 GEOGRAPHIC PRESENCE
22.30.4 PRODUCT PORTFOLIO
22.30.5 RECENT DEVELOPMENTS
23 CONCLUSION
24 QUESTIONNAIRE
25 ABOUT DATA BRIDGE MARKET RESEARCH
